drugset / Trial / NCT07570082
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.
Timeline
- Start
- 2026-05-28
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atumelnant | Small molecule | — | — |
| Subject | Carbamazepine | Small molecule | — | — |
| Subject | Digoxin | Other / unclassified | — | — |
| Subject | Metformin | Small molecule | — | — |
| Subject | Midazolam | Small molecule | — | — |
Indications
No indication recorded.